No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BPMC240816C160000
- 0.90
- +0.30+50.00%
15min DelayTrading Jul 22 09:30 ET
0.90High0.90Low
0.90Open0.60Pre Close1 Volume3 Open Interest160.00Strike Price90.00Turnover81.16%IV38.43%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type0.0856Delta0.0063Gamma129.15Leverage Ratio-0.0768Theta0.0063Rho11.05Eff Leverage0.0480Vega
Intraday
- 5D
- Daily
News
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $150
Stifel analyst Bradley Canino maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $150.According to TipRanks data, the analyst has a success rate of 53.9%
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Oppenheimer's Best SMID-cap Ideas: AI, Health, Obesity Drugs, and More
Express News | Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
4
Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.
3
The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.
Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.
1
Read more